RESEARCH & PUBLICATIONS

EDUCATION AND CLINICALLY-RELEVANT RESOURCES
Urine Drug Monitoring: Opioids
Monitoring patient usage of scheduled controlled substances is a major concern and responsibility of prescribing clinicians. This handbook collects the most effective techniques for monitoring pharmacotherapy, with an emphasis on opioids, into a practical, objective and comprehensive strategy. DownloadUrine Drug Monitoring Opioids.pdf
Unchain Your Brain: 10 Steps to Breaking the Addictions that Steal Your Life
Authored by: Daniel G. Amen, MD and David E. Smith, MD Unchain Your Brain: 10 Steps to Breaking the Addictions that Steal Your Life is a practical, easy-to-follow, step-by-step program that shows you how to boost your brain so you can kick your bad habits. When you have a healthy brain, it makes it so much easier to stick with a program designed to help you quit smoking, drinking, gambling, doing drugs, overeating, or whatever your addiction may be. Purchase the Book
Understanding Elimination Patterns with Creatinine Adjusted Drug Values
Creatinine is a product of muscle contraction. Because it is produced from within and released into body fluids at a relatively constant rate, the level of creatinine in urine may be used as an indication of body hydration. Since measured drug levels can fluctuate with the level of creatinine, a key aspect of your laboratory testing is creatinine adjustment. With creatinine adjusted drug levels, you can better monitor drug usage and redefine program goals to increase treatment eff ectiveness. Creatinine adjusted values are for clinical pharmacokinetic comparison only; these values are not intended for forensic or punitive use. DownloadCreatinine Adjusted Drug Values.pdf
Withdrawal from Buprenorphine/Naloxone and Maintenance with a Natural Dopaminergic Agonist: A Cautionary Note
Authors: Blum K, Oscar-Berman M, Femino J, Waite RL, Benya L, Giordano J, Borsten J, Downs WB, Braverman ER, Loehmann R, Dushaj K, Han D, Simpatico T, Hauser M, Barh D, McLaughlin T. While numerous studies support the efficacy of methadone and buprenorphine for the stabilization and maintenance of opioid dependence, clinically significant opioid withdrawal symptoms occur upon tapering and cessation of dosage. We present a case study of a 35 year old Caucasian female (Krissie) who was prescribed increasing dosages of prescription opioids after carpel tunnel surgery secondary to chronic pain from reflex sympathetic dystrophy and fibromyalgia. Read the Full Article
Neurogenetic Impairments of Brain Reward Circuitry Links to Reward Deficiency Syndrome (RDS): Potential Nutrigenomic Induced Dopaminergic Activation
Authors: Blum K, Oscar-Berman M, Giordano J, Downs B, Simpatico T, Han D, Femino J. Work from our laboratory in both in-patient and outpatient facilities utilizing the Comprehensive Analysis of Reported Drugs (CARD)™ found a significant lack of compliance to prescribed treatment medications and a lack of abstinence from drugs of abuse during active recovery. This unpublished, ongoing research provides an impetus to develop accurate genetic diagnosis and holistic approaches that will safely activate brain reward circuitry in the mesolimbic dopamine system. This editorial focuses on the neurogenetics of brain reward systems with particular reference to genes related to dopaminergic function. Read the Full Article
Urinary Analytes for Patients Taking Opiate-Based Medications
Quantitative urine analysis by UPLC-MS/MS has the capability of detecting analytes of frequently prescribed opiate-based medications; codeine, morphine, hydrocodone, hydromorphone, oxycodone, and oxymorphone. Download: Opiate Metabolism.pdf
Urinary Analytes for Patients Taking Benzodiazepine Medications
Quantitative urine analysis by UPLC-MS/MS has the capability of detecting analytes of frequently prescribed benzodiazepine medications: alprazolam, chlordiazepoxide, clonazepam, clorazepate, diazepam, flurazepam, lorazepam, oxazepam, prazepam, temazepam, and triazolam. Download: Benzo Metabolism.pdf
Systematic Evaluation of “Compliance” to Prescribed Treatment Medications and “Abstinence” from Psychoactive Drug Abuse in Chemical Dependence Programs: Data from the Comprehensive Analysis of Reported Drugs
Authors: Kenneth Blum, David Han, John Femino, David E. Smith, Scott Saunders, Thomas Simpatico, Stephen J. Schoenthaler, Marlene Oscar-Berman, Mark S. Gold This is the first quantitative analysis of data from urine drug tests for compliance to treatment medications and abstinence from drug abuse across “levels of care” in six eastern states of America. Comprehensive Analysis of Reported Drugs (CARD) data was used in this post-hoc retrospective observational study from 10,570 patients, filtered to include a total of 2,919 patients prescribed at least one treatment medication during 2010 and 2011. Read the Full Article
Quantitative Electroencephalography Analysis (qEEG) of Neuro-Electro- Adaptive Therapy 12™ [NEAT12] Up-Regulates Cortical Potentials in an Alcoholic during Protracted Abstinence: Putative Anti-Craving Implications
Authors: Roger L Waite, Marlene Oscar-Berman, Eric R Braverman, Debmalya Barh and Kenneth Blum Cranial electrotherapy stimulation (CES) is a noninvasive therapy that has been used for decades in the United States to treat anxiety, depression, and insomnia in the general population. The effectiveness of CES has been questioned by many and its use is considered controversial. In this study we are presenting data on one alcoholic patient using a newly engineered device we call Neuro-Electro-Adaptive Therapy 12™ [NEAT12]. This hybrid device utilizes TENS current characteristics yielding CES effects. This device has been found to primarily target the excitation of the Cingulate Gyrus region of the brain. Read the Full Article
Neurophysiological Measures and Alcohol Use Disorder (AUD): Hypothesizing Links between Clinical Severity Index and Molecular Neurobiological Patterns
Authors: Mario Vitali, Carmen Napolitano, Marlene Oscar-Berman, Simona Flamminii Minuto, Gemma Battagliese, Maria Luisa Attilia, Eric R Braverman, Marina Romeo, Kenneth Blum and Mauro Ceccant In 1987, Cloninger proposed a clinical description and classification of different personality traits genetically defined and independent from each other. Moreover, he elaborated a specific test the TCI to investigate these traits/states. The study of craving in Alcohol Use Disorder (AUD) assumed a greater significance, since ever more data seems to suggest a direct correlation between high levels of craving and a higher risk of relapse in alcoholics. Thus, our study aim is to explore the possible correlations among TCI linked molecular neurobiological pattern(s), craving and alcohol addiction severity measures in a sample of Italian alcoholics. Read the Full Article
Drug Abuse Relapse Rates Linked to Level of Education: Can We Repair Hypodopaminergic-Induced Cognitive Decline With Nutrient Therapy?
Authors: Blum K1, Schoenthaler SJ, Oscar-Berman M, Giordano J, Madigan MA, Braverman ER, Han D. It is well known that athletes are among individuals with high risk for all reward deficiency syndrome (RDS) behaviors, including substance use disorder (SUD). Comparing patient demographics and relapse rates in chemical dependence programs is pertinent because demographics may affect outcomes. Increased risk for relapse and lower academic achievement were found to have a significant association in recent outcome data from a holistic treatment center (HTC) located in North Miami Beach, FL. Read the Full Article
When the Servant Becomes the Master
Authored by: Jason Powers, MD The definitive guide to addiction that addresses misinformation and stigma, humanizes the disease within a framework of science, research, and personal experience, and provides a wealth of information on the various forms addiction takes as well as rich data regarding treatments. Purchase the Book
Uppers, Downers, All Arounders
Authored by: Darryl S. Inaba, PharmD and William Cohen This highly regarded textbook from one of the leaders in drug education has been adopted for courses in over 400 colleges and universities nationwide and is featured in the training curriculum of the DEA, and many law enforcement programs. It is considered by many to be the standard reference of AOD counseling certification. Authored by two of the most respected authorities in the field of addiction treatment, the content provides the reader with perceptive insights into the complexities of drug abuse, compulsive behaviors, addiction, treatment, recovery and prevention. Purchase the Book
Molecular Neurobiology of Addiction Recovery: The 12 Steps Program and Fellowship
Authored by: John Giordano, Kenneth Blum, Mark Gold, Marlene Oscar-­Berman, Scott Teitelbaum, and John Femino Humans are biologically programmed to seek out pleasurable experiences.  These experiences are processed in the mesolimbic system, also referred to as the “reward center” of the brain, where a number of chemical messengers work in concert to provide a net release of dopamine in the Nucleus Accumbens.  In some genetically predisposed individuals, addiction occurs when the mechanisms of the mesolimbic system are disrupted by the use of various drugs of abuse. Since Alcoholics Anonymous was founded in 1935, it’s 12 step program of spiritual and character development has helped countless alcoholics and drug addicts curb their self-­destructive behaviors.  However, the program was developed at a time when comparatively little was known about the function of the brain and it has never been studied scientifically. This is the first book to take a systematic look at the molecular neurobiology associated with each of the 12 steps and to review the significant body of addiction research literature that is pertinent to the program.­ Purchase the Book
Medically-Assisted Treatment (MAT): The Counseling SidE
Presented by: Shannon Garrett, LGSW, LCADC.  An Educational Lecture entitled Medically-Assisted Treatment (MAT): The Counseling Side. Presented at the 2016 Virginia Summer Institute for Addiction Studies. DownloadMAT The Counseling Side – SGarrett VSAIS 2016.pdf  PERMISSIONS:  Please do not reproduce without written permission from Dominion Diagnostics and Shannon Garrett, LGSW, LCADC
Scroll to Top

Need Help?

CURRENT CUSTOMERS:

877.734.9600

WANT TO WORK WITH US?

401.667.5688

Mark Peters, Chief Financial Officer of Dominion Diagnostics

Mark Peters

Chief Financial Officer

Mark Peters joined Dominion Diagnostics in 2021 and serves as the company’s Chief Financial Officer. Mr. Peters is responsible for Dominion’s Financial Planning & Analysis, Accounting, and Revenue Cycle Management functions. He has over 25 years of financial, operations, and strategic management experience in public, private equity, and venture capital backed healthcare companies.

His experience includes executive roles at Seikagaku Corporation (Tokyo Stock Exchange), IST (now part of Integra LifeSciences), Health Language (now part of Wolters Kluwer), and management positions with IBM and PricewaterhouseCoopers.  

Mr. Peters is a licensed CPA and graduated with an MBA in Finance from The University of Notre Dame and a BBA in Accounting from The University of Texas. In his personal time, he enjoys the outdoors, sports, reading, and spending time with his family.

Mark A. McSally, Esq.

Chief Operating Officer / General Counsel

Mark A. McSally, Esq. joined Dominion Diagnostics in 1999 as Outside General Counsel and moved internally in 2006 to assume the role of Corporate Counsel.  He currently serves as Dominion’s Chief Operating Officer and General Counsel.

Mr. McSally is responsible for all aspects of Dominion’s legal and regulatory needs, including government relations and corporate compliance.  As Chief Operating Officer, he is involved in all aspects of the operational management of Dominion Diagnostics, providing oversight to the Payer Relations, Clinical Services, Laboratory, Research and Development and Client Services teams. 

Mr. McSally is a seasoned attorney with deep roots in Rhode Island’s South County. Mr. McSally holds a Bachelor of Arts in History, with honors, from the College of the Holy Cross and a Juris Doctorate, with honors, from Suffolk University Law School.  He has and continues to serve on a number of community boards.

Luke Jessen

Vice President, Sales & Marketing

Luke Jessen joined Dominion Diagnostics in 2010 and currently serves as its Vice President of Sales & Marketing.  Luke has over twenty-three years of experience in healthcare, including fifteen years in diagnostics. 

Prior to joining Dominion Diagnostics, Luke spent eight years working in pharmaceuticals and two and a half years educating health care providers on appropriate opioid prescribing as President & Founder of Opioid Compliance Consulting.  After Opioid Compliance Consulting was acquired by Riverside Partners in 2010, Luke joined Dominion Diagnostics as Western Regional Sales Director. 

Luke has a consistent track record of building highly successful sales teams and driving clinically appropriate results. 

He holds a Bachelor of Arts in Political Science from The Colorado College in Colorado Springs, Colorado.  In his free time, Luke enjoys spending time with his family, surfing, mountain biking, fly fishing, hiking, snow/water skiing, and playing pickleball.  Luke also volunteers in his community at Cherry Hills Community Church, where he serves as a Ruling Elder. 

John Hearn

Vice President, Business Development & Payer Relations

John joined Dominion Diagnostics in 2018. In addition to business development responsibilities at Dominion Diagnostics, he manages the payer relations and inside sales teams. John has over 25 years of business development experience with 14 being in the laboratory space.

Before joining Dominion Diagnostics, John was the Chief Marketing Officer for Pathway Diagnostics. His responsibilities included, business development, managing outside sales, compliance, market and business strategy as well as lab operations. Prior to Pathway Diagnostics, he worked for Cordant Health Solutions, where he sold and managed a 5000 specimen a month book of business that grossed over $48 million in annual revenue as well as managed the Southeast sales team. In 2010, he was hired by Quest Diagnostics to be an account executive. His call points were all specialties including OBGYN and pain management.

Prior to working in the healthcare space, he had a sales role with Fidelity Information Services in their risk management and payment processing division. During his career and with two fortune 500 companies, he has won multiple president club awards.

John has a Bachelor of Business Administration degree from the University of Mississippi. John enjoys being outdoors, playing golf and tennis, watching his three kids play sports and traveling with his family.

Jeff Nally

Senior Vice President, RCM & Corporate Compliance Officer

Jeff joined Dominion Diagnostics in 2014 and currently serves as the SVP of Revenue Cycle Management and is also the company’s Corporate Compliance Officer. Jeff has spent his 25+ year career in finance and the past 20 years focused on healthcare revenue cycle management.

Prior to Dominion Diagnostics Jeff lead the shared services center as the Senior Finance Director for The Mentor Network a national network of local health and human services offering community-based services to adults and children with intellectual and development disabilities. Prior to The Mentor Network Jeff spent 9 years at Perkinelmer leaving as the Director of Insurance and Consumer Billing over seeing revenue cycle management in multiple diagnostic laboratories.

Jeff drives revenue cycle management excellence through streamlined operations and better workflow. Jeff can assess distressed situations, quickly managing necessary change while delivering and improving results and employee success.

In his personal time, he enjoys golf, local sports, and spending time with family and friends.  Jeff is certified in health care compliance (CHC) and has a bachelor’s degree from Curry College.

Denise Driscoll, SPHR, CCP

Vice President, Human Resources

Denise Driscoll is an experienced human resource leader across various industry sectors. Her prior experience includes working for national and global organizations.

Ms. Driscoll’s prior healthcare experience includes the creation of a HR shared services organization for a regional healthcare system.  She’s led programs in support of highly engaged employee populations.  She has significant organizational design, compensation, and benefit management experience as well as in-depth experience with mergers and acquisitions. Her employee relations record includes creating and implementing performance and development systems in support of high-performing companies.

At Dominion Diagnostics, Ms. Driscoll is responsible for organizational health and is the senior executive sponsor of the cross-functional Employee Success Team, which fosters employee engagement through communication, wellness initiatives, and programs that promote connection and a strong sense of community.

Denise has a B.A. in Psychology from Drew University, and an M.B.A. with a concentration in HR from San Francisco State University.  In her free time, she enjoys yoga, hiking, listening to live music, and kayaking. Denise is active with the Rhode Island Community Food Bank, where she is Head of the HR Committee and serves on the Board.

David J. Molusis

Vice President, Information Technology

David J. Molusis joined Dominion Diagnostics in 2015 as Vice President of Information Technology. Mr. Molusis has over 25 years of experience as an accomplished healthcare IT leader and administrator. 

Prior to Dominion Diagnostics, Mr. Molusis held the position of Vice President, Sales & Marketing at Nashville based, Common Cents Systems, a software development firm for reference laboratories. Prior to that as Vice President & CIO at Clinical Laboratory Partners, a member of Hartford Health Care Corporation’s integrated healthcare delivery system. Before his role at Clinical Laboratory Partners, Mr. Molusis held a variety of career evolving positions, including Chief Information Officer, at VNA Health Care, the largest home health care organization in Connecticut.  Earlier in his career, he held various roles in IT, project management, software development and optimization. 

Mr. Molusis is also a contributing author to the industry publications of Laboratory Economics in 2007, The Dark Report in 2011, and most recently, Advance for Administrators of the Laboratory in 2014. 

Mr. Molusis holds a Master’s degree in Information Management from Rensselaer Polytechnic Institute, a Bachelor’s degree in Business Administration from Western Connecticut State University and project management certification from Villanova University. In his personal time, he enjoys the beach, skiing, travel, and spending time with his family and friends between Connecticut, Southern Maine and Florida. 

Charlene Johnson, PhD

Senior Vice President, Laboratory Operations & Quality

Dr. Charlene Johnson first joined Dominion Diagnostics in 2003 as the Director of Molecular Testing.  In 2009, she became the Assistant Laboratory Director for Dominion’s Rhode Island and Vermont laboratories. Dr. Johnson assumed the role of Laboratory Director in 2011, followed by Vice President of Laboratory Operations and Laboratory Director in 2013, and was promoted to serve as the company’s Senior Vice President, Laboratory Operations & Quality in 2021.

Under Dr. Johnson’s exemplary leadership, Dominion’s laboratories have expanded tremendously in both capacity and testing capabilities.  She has driven significant achievements in laboratory operations, research and development, and strategic growth.  The company counts on Dr. Johnson’s expertise and guidance to uphold its reputation for sound science and laboratory integrity. 

Prior to joining Dominion, Dr. Johnson worked as a Senior Research Fellow at the University of Texas Health Science Center in Houston, Texas. 

Dr. Johnson holds a Bachelor of Science from the College of William and Mary and received her PhD from Virginia Commonwealth University/Medical College of Virginia.

Carin Johnson

Senior Vice President, Customer Operations

Carin joined the organization in 2015 and currently holds the position of Senior Vice President of Customer Operations. With a career spanning over 30 years in healthcare management, including 16 years of specialization in laboratory diagnostics, she brings invaluable expertise to the industry.

Before joining Dominion Diagnostics, Carin served as the Field Operations Director at Calloway Labs, where she oversaw and directed nationwide operations. In this role, she played a integral role in driving operational improvements, with a strong focus on enhancing the customer experience. This resulted in increased productivity and streamlined procedures, making a substantial impact during her tenure.

Carin holds a Bachelor of Science in Business Management from the University of Maryland. In her free time, she enjoys spending time with her family, as well as running, hiking, and traveling.

Robert M. Garvey, Jr.

Chief Executive Officer

Bob joined Dominion Diagnostics in 2011 and serves as its Chief Executive Officer. He has over 35 years of experience in healthcare, including over three decades of leadership in laboratory diagnostics and diagnostic imaging. 

Prior to Dominion Diagnostics, Bob ran the Northeast division of Laboratory Corporation of America as the Senior Vice President, which generated over $800M in annual revenue. He drove considerable organizational change to improve quality, service levels and foster growth.

Before his role at LabCorp, he spent 12 years at Quest Diagnostics where he held various Vice President and General Manager roles. Early in his career, he held roles in sales and sales management at GE Healthcare. Bob has a proven track record of growing healthcare businesses and developing high performing teams.

He holds a Bachelor of Science in Finance from the University of Massachusetts – Lowell. In his personal time, he enjoys tennis, golf, hockey, traveling, reading and spending time with his family.